Back to search results

Phase I pH MRI Based Resection for Glioblastoma

This study is testing a new way to remove glioblastoma, a type of brain tumor, using a special MRI. Glioblastoma is hard to see completely during surgery, but this new pH (acid-base) related MRI might help doctors see more of the tumor that has spread. In this study, called a Phase I trial, doctors will use this special MRI to guide surgery and remove more of the tumor. They want to see if this new method is safe and well-tolerated in patients. You might be able to join if you are an adult with newly diagnosed or recurring glioblastoma, have a good performance status (Karnofsky Performance Scale of 70 or higher), and meet other criteria. The main goal is to check for any problems related to the surgery after one month. The current status of this study is unclear.

Study design
This is a Phase I interventional study, meaning it's an early safety study. It plans to enroll 12 participants.
What's involved
You would undergo a special pH MRI, followed by surgery based on the MRI results. The study will assess adverse events for one month after surgery.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, resection-related adverse events, is measured at 1 month.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07218367

Phase I Trial of pH Resections of GBM at VA

Not Yet Recruiting
PHASE1Ages 18+InterventionalTreatment
VA Office of Research and Development
~12 participants
Updated 2026-02-13 on ClinicalTrials.gov
What's tested:pH MRI based resection of GBM

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Resection related adverse events
Measured over 1 month

Conditions

Glioblastoma

Explore related trials

Glioblastoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Kunal S Patel · PRINCIPAL_INVESTIGATOR · VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Who to contact

Kunal S Patel
[email protected]
(310) 478-3711
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to provide written informed consent
Karnofsky Performance Scale (KPS) of 70 or higher
Suspected, newly diagnosed or recurrent IDH wild type WHO IV glioblastoma presenting as an intra-axial
Expansile contrast-enhancing mass without evidence of metastatic disease

Exclusion

Diagnostic uncertainty such as history of extracranial malignancy or autoimmune disease
Medical conditions prohibiting anesthesia or surgery
Tumors involving eloquent brain areas as defined by MRI signal
primary motor cortex, primary sensory cortex, sensorimotor fibers, primary language areas, arcuate fasciculus

What this trial measures

  • Resection related adverse events1 month

    Safety as described by surgical complication rates by the data safety and monitoring board